MediWound (NASDAQ:MDWD - Get Free Report) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.58, Zacks reports. The firm had revenue of $3.96 million for the quarter, compared to the consensus estimate of $5.20 million. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same period in the previous year, the company earned ($1.05) earnings per share. MediWound updated its FY 2025 guidance to EPS.
MediWound Trading Up 0.1%
MDWD stock traded up $0.03 during mid-day trading on Monday, hitting $20.37. The stock had a trading volume of 44,100 shares, compared to its average volume of 91,476. The firm has a fifty day simple moving average of $17.46 and a 200 day simple moving average of $17.63. The firm has a market capitalization of $220.16 million, a P/E ratio of -7.02 and a beta of 0.30. MediWound has a 52 week low of $12.78 and a 52 week high of $24.00.
Institutional Trading of MediWound
A hedge fund recently raised its stake in MediWound stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in MediWound Ltd. (NASDAQ:MDWD - Free Report) by 22.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,452 shares of the biopharmaceutical company's stock after acquiring an additional 999 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned about 0.05% of MediWound worth $85,000 at the end of the most recent quarter. 46.83% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of analysts have issued reports on the stock. Craig Hallum began coverage on shares of MediWound in a report on Friday, February 28th. They issued a "buy" rating and a $39.00 price objective for the company. Alliance Global Partners initiated coverage on MediWound in a research note on Friday, May 2nd. They issued a "buy" rating and a $25.00 price target for the company. HC Wainwright set a $31.00 price target on MediWound and gave the stock a "buy" rating in a research report on Thursday. Finally, Wall Street Zen upgraded MediWound to a "sell" rating in a research note on Friday, March 21st. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, MediWound currently has an average rating of "Moderate Buy" and an average target price of $31.25.
View Our Latest Analysis on MediWound
MediWound Company Profile
(
Get Free Report)
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Featured Stories
Before you consider MediWound, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediWound wasn't on the list.
While MediWound currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
